USFDA approves Roche’s lymphoma therapy Reuters Dec 26, 2022 The drug, known chemically as mosunetuzumab, can be administered at a hospital’s outpatient centre, unlike some other follicular…
CHMP recommends EU conditional approval of Roche’s antibody Mosunetuzumab for people with relapsed… EP News Bureau Apr 25, 2022 If approved, Mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat Follicular Lymphoma…
Bispecific antibodies will mature after 2021, $6bn estimated sales in oncology by 2025: GlobalData EP News Bureau Sep 29, 2020 There are106 bispecific antibody molecules in the pipeline and 263 ongoing/planning to enrol clinical trials involving a…
